Loading...

AMLX AMYLYX PHARMACEUTICALS INC Product Launches 8-K Filing

MYLY

MLX

AMYLYX PHARMACEUTICALS INC

(AMLX)

2025 8-K

Corporate Presentation Update

Financial Results

New Drug Candidate

Financial Results Update

Stock Offering Announcement

Program Discontinuation

Financial Statements

Financial Statements

Financial Results

Collaboration Announcement

Financial Results

Clinical Trial Results

Financial Results Announcement

Acquisition of Avexitide Asset

Asset Purchase Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Management Change

Financial Results Announcement

Financial Results Announcement

Conference Call

Rejection of Marketing Auth...

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Conference Presentation

External Links:

On August 27, 2025, Amylyx Pharmaceuticals announced the discontinuation of its ORION program for AMX0035 in adults with progressive supranuclear palsy, due to lack of efficacy compared to placebo. The Phase 2b trial and open-label extension will end, and the Phase 3 portion will not be initiated.

AI Assistant

AMYLYX PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.